Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AdvaMed Says New Study Will Support Revamping Of Japan Reimbursement

This article was originally published in The Gray Sheet

Executive Summary

A detailed study comparing the cost of bringing medical devices to market in Japan to that of doing so in the U.S. is due out soon from AdvaMed

You may also be interested in...

Chilly Japanese Medical Device Climate Draws Fire From Hill, Industry

Japan's regulatory and reimbursement systems came under fire this week from lawmakers on Capitol Hill and attendees of AdvaMed's international conference in Arlington, Va

AdvaMed President Ubl Sets Ambitious FDA Performance, International Goals

AdvaMed President Steve Ubl aims to have FDA meeting a 180-day review deadline for expedited PMAs in the next three to five years and to revamp Japan's reimbursement system in the next two years

Japan’s ’05 Reforms Will Increase Efficiency, Reflect ’04 Industry Effort

Faster reviews of low-risk medical devices in Japan are on the horizon as the fledgling Pharmaceutical & Medical Devices Agency prepares to implement new review processes, effective April 1




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts